Leerink Partnrs Weighs in on Myriad Genetics Q2 Earnings

Myriad Genetics, Inc. (NASDAQ:MYGN) – Leerink Partnrs issued their Q2 2026 earnings per share (EPS) estimates for Myriad Genetics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst P. Souda expects that the company will post earnings per share of ($0.02) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Myriad Genetics’ current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Myriad Genetics’ Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at $0.02 EPS.

Other analysts have also issued research reports about the stock. Stephens reaffirmed an “equal weight” rating and set a $20.00 price target on shares of Myriad Genetics in a research report on Thursday, January 16th. Raymond James reissued an “outperform” rating and set a $19.00 target price (down previously from $27.00) on shares of Myriad Genetics in a research note on Tuesday. Craig Hallum initiated coverage on Myriad Genetics in a research note on Wednesday, February 12th. They issued a “buy” rating and a $29.00 price target on the stock. UBS Group lowered their price target on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Bank of America decreased their target price on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $22.14.

Myriad Genetics Price Performance

Shares of MYGN stock opened at $10.73 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The company has a market capitalization of $976.81 million, a PE ratio of -8.25 and a beta of 1.88. The firm’s 50-day moving average is $13.28 and its two-hundred day moving average is $19.04. Myriad Genetics has a 12 month low of $9.76 and a 12 month high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The company had revenue of $210.60 million for the quarter, compared to analysts’ expectations of $210.35 million. During the same quarter in the prior year, the firm earned ($0.12) EPS.

Institutional Investors Weigh In On Myriad Genetics

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning grew its stake in shares of Myriad Genetics by 9.8% in the third quarter. Creative Planning now owns 9,949 shares of the company’s stock worth $273,000 after acquiring an additional 892 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Myriad Genetics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after purchasing an additional 583 shares during the period. Nisa Investment Advisors LLC grew its stake in Myriad Genetics by 182.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 11,417 shares of the company’s stock worth $313,000 after purchasing an additional 7,381 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Myriad Genetics by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,468 shares of the company’s stock worth $478,000 after purchasing an additional 6,834 shares during the period. Finally, New York State Teachers Retirement System raised its position in Myriad Genetics by 4.4% in the 3rd quarter. New York State Teachers Retirement System now owns 73,900 shares of the company’s stock valued at $2,024,000 after purchasing an additional 3,102 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.